ReviewInternational journal of environmental research and public health2021
Understanding the Challenges and Uncertainties of Seroprevalence Studies for SARS-CoV-2.
Review in International journal of environmental research and public health, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Potential for Bias in Prevalence Estimates when Not Accounting for Test Sensitivity and Specificity: A Systematic Review of COVID-19 Seroprevalence Studies.International journal of public health · 2025Pooled it
- The COVID-19 Pandemic and Health and Care Workers: Findings From a Systematic Review and Meta-Analysis (2020-2021).International journal of public health · 2023Pooled it
- SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Resolving parameter uncertainty in SIR models through population-level serological surveillance: A synthetic study.Infectious Disease Modelling · 2026Article
- COVID19 Sero-epidemiology and vaccine uptake in two Southern Nigerian clinics.PLOS global public health · 2026Article
- Dealing with differential misclassification of an outcome or a covariate in association studies with an internally validated sample selected not at random.BMC medical research methodology · 2025Article
- Tracking SARS-CoV-2 seroprevalence in frontline healthcare workers at the beginning of COVID-19 pandemic and reliability of serological laboratory interpretation: a prospective cohort study.Virology journal · 2025Article
- COVID-19 Seroprevalence in Romania: Insights from a Nationwide Antibody Study.Epidemiologia (Basel, Switzerland) · 2025Article
- Generalizability of anti-SARS-CoV-2 seroprevalence estimates to the Montréal pediatric population: a comparison between 2 weighting methods.American journal of epidemiology · 2025Article
- Two-stage cluster sampling to assess SARS-CoV-2 seroprevalence without pre-enumeration: An example from Madagascar.PloS one · 2025Observational
- Population-based cross-sectional seroprevalence study of SARS-CoV-2 infection in urban residential areas in Ghana.BMJ public health · 2025Article
- High SARS-CoV-2 Exposure in Rural Southern Mozambique After Four Waves of COVID-19: Community-Based Seroepidemiological Surveys.Influenza and other respiratory viruses · 2024Article
- Seroprevalence of SARS-CoV-2 IgG in blood donors in a teaching institute from Western part of Maharashtra.Journal of family medicine and primary care · 2024Article
- Prevalence of SARS-CoV-2-specific antibodies in a sample of the Lithuanian population-based study in Spring 2023.Heliyon · 2024Article
- Gaining further insights into the COVID-19 pandemic in Australia: Evidence using capture-recapture methods.Heliyon · 2024Article
- The importance of prevalence and pre-test probability on the microbiological diagnosis of SARS-CoV-2: the case of Spain in 2020.Revista espanola de quimioterapia : publicacion oficial de la Sociedad Espanola de Quimioterapia · 2023Article
- Development of an Affordable ELISA Targeting the SARS-CoV-2 Nucleocapsid and Its Application to Samples from the Ongoing COVID-19 Epidemic in Ghana.Molecular diagnosis & therapy · 2023Article
- Article
- Article
- Age-specific SARS-CoV-2 infection fatality rates derived from serological data vary with income and income inequality.PloS one · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
SARS-CoV-2 continues to widely circulate in populations globally. Underdetection is acknowledged and is problematic when attempting to capture the true prevalence. Seroprevalence studies, where blood samples from a population sample are tested for SARS-CoV-2 antibodies that react to the SARS-CoV-2 virus, are a common method for estimating the proportion of people previously infected with the virus in a given population. However, obtaining reliable estimates from seroprevalence studies is challenging for a number of reasons, and the uncertainty in the results is often overlooked by scientists, policy makers, and the media. This paper reviews the methodological issues that arise in designing these studies, and the main sources of uncertainty that affect the results. We discuss the choice of study population, recruitment of subjects, uncertainty surrounding the accuracy of antibody tests, and the relationship between antibodies and infection over time. Understanding these issues can help the reader to interpret and critically evaluate the results of seroprevalence studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.